A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super responders’ to Merck & Co’s Keytruda (pembrolizumab) immunotherapy i
Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
